middle.news
Cynata Builds Momentum with Three Clinical Trials Nearing Key Readouts
2:22pm on Wednesday 30th of July, 2025 AEST
•
Biotechnology
Read Story
Cynata Builds Momentum with Three Clinical Trials Nearing Key Readouts
2:22pm on Wednesday 30th of July, 2025 AEST
Key Points
Phase 2 aGvHD trial over 75% enrolled, results expected H1 2026
Phase 3 osteoarthritis trial fully enrolled with top-line data due Feb-Apr 2026
Kidney transplant trial cohort 1 treatment complete, DSMB review due Q4 2025
Strong cash position of $5 million plus anticipated $1.25 million R&D tax rebate
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Cynata Therapeutics (ASX:CYP)
OPEN ARTICLE